Advances in Antiviral Drug Design
Edited by Erik De Clercq
Normal Price: $232.00
Your Price: $208.80 AUD, inc. GST
Shipping: $7.95 per order
You Save: $23.20! (10% off normal price)
Plus...earn $10.44 in Boomerang Bucks
Availability: Available to Backorder, No Due Date for Supply, Not for Xmas
Advances in Antiviral Drug Design by Erik De Clercq
Book DescriptionThe fourth volume of "Advances in Antiviral Drug Design" is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections. First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use. Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young. Third, as all currently available PIs can be described as 'peptidomimetic', and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister. Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim. Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone 'upstream' in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents. Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses. The six topics covered in this fourth volume of "Advances in Antiviral Drug Design" are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses.
Buy Advances in Antiviral Drug Design book by Erik De Clercq from Australia's Online Bookstore, Boomerang Books.
Book DetailsISBN: 9780444506023
(152mm x 229mm x 15mm)
Imprint: Elsevier Science Ltd
Publisher: Elsevier Science & Technology
Publish Date: 17-Dec-2003
Country of Publication: United Kingdom
Books By Author Erik De Clercq
Anti-Viral Agents, Hardback (September 2013)
Suitable for pharmacologists, immunologists and biochemists alike, this title explores the antiviral agents. It includes chapters that cover such topics as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSV.
Antiviral Drug Strategies, Hardback (April 2011)
* Deadly viruses like AIDS, SARS, Ebola and others still cannot be satisfactorily controlled. Finding new antivirals is therefore a prime goal in pharma research. * Erik De Clercq is the world authority on small molecule antiviral drugs and has developed more new antivirals than anyone else.
Advances in Antiviral Drug Design, Hardback (July 2007)» View all books by Erik De Clercq
Reviews the conceptual design and chemical synthesis of new antiviral compounds. This volume discusses their structure-activity relationship, mechanism and targets of action, pharmacological behavior, antiviral activity spectrum, and therapeutic potential for clinical use.
» Have you read this book? We'd like to know what you think about it - write a review about Advances in Antiviral Drug Design book by Erik De Clercq and you'll earn 50c in Boomerang Bucks loyalty dollars (you must be a member - it's free to sign up!)
Bestselling Books: Our Current Bestsellers | Australia's Hottest 1000 Books | Bestselling Fiction | Bestselling Crime Mysteries and Thrillers | Bestselling Non Fiction Books | Bestselling Sport Books | Bestselling Gardening and Handicrafts Books | Bestselling Biographies | Bestselling Food and Drink | Bestselling History | Bestselling Travel Books | Bestselling School Textbooks & Study Guides | Bestselling Children's General Non-Fiction | Bestselling Young Adult Fiction | Bestselling Children's Fiction | Bestselling Picture Books | Top 100 US Bestsellers
Phone: 1300 36 33 32 (9am-2pm Mon-Fri AEST) - International: +61 2 9960 7998 - Online Form
Address: Boomerang Books, 878 Military Road, Mosman Junction, NSW, 2088
© 2003-2016. All Rights Reserved. Eclipse Commerce Pty Ltd - ACN: 122 110 687 - ABN: 49 122 110 687
For every $20 you spend on books, you will receive $1 in Boomerang Bucks loyalty dollars. You can use your Boomerang Bucks as a credit towards a future purchase from Boomerang Books. Note that you must be a Member (free to sign up) and that conditions do apply.